We enjoyed welcoming delegates to our first virtual breakfast briefing earlier this month discussing the trends shaping medical and regulatory affairs in 2021. In this round-up, we share some of the key discussion points- from a post-Brexit MHRA, to the new ILAP scheme. We look forward to exploring these issues further in future PharmaMedic events soon.
As 2021 gets underway, in the context of continued pandemic response and post-Brexit environment, the role of regulatory affairs in pharma is likely to be more instrumental than ever. In this article, we share a preview of the key regulatory trends that Dr Zubair Hussain will discuss at our upcoming breakfast briefing on the 10th February. Read on to learn more about the ways regulatory affairs is set to underpin innovation and sign up to attend our virtual briefing.
We marked our 5-year anniversary as a client of the London Bioscience Innovation Centre (LBIC) recently and featured in its Winter newsletter alongside Prokarium, MicrosensDx and VirTus and others.
2020 was certainly one of the most unusual years we can recall. Thank you to our clients, consultants and readers for following our news stories. We wrote on a range of topics and we recap the most widely read articles of last year in this short read.
PharmaMedic is delighted to announce the launch of a new series of virtual events starting with a breakfast briefing on Wednesday 10th February 2021 at 08:00 am. In this first event, we will cover the 2021 Medical and Regulatory Affairs Outlook. For full details and how to register please read further.
PharmaMedic was delighted to support and sponsor the Excellence in Rare Diseases and Orphan Drugs category at the recent PMEA awards. Read our article to find out more.
In our latest article, we explore how PMC supports Dr Kathrine Scott of Gedeon Richter with new product launches and day to day copy approval. Read on to learn how we are helping this small medical team make a real impact.
The number of clinical trials for orphan conditions has grown significantly in the past decade. New advances in genomics and artificial intelligence also stand to improve prospects for patients with rare diseases. Read the article to learn how PharmaMedic helps translate often complex science into stakeholder value for rare disease sponsors and deliver new medicines to patients who need them.
PharmaMedic Consultancy is delighted to announce its sponsorship of the ‘Excellence in Rare Diseases and Orphan Drugs" category at the 2020 Pharmaceutical Market Excellence Awards (PMEA).
From 1 January 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) will be making independent regulatory decisions. Guidelines are in place, and the ABPI has called for support to help sponsors navigate the changes. Read on to learn more about this new era of independence for the agency.
